MiR-494-3p promotes PI3K/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN. 2018

Hui Lin, and Zhi-Ping Huang, and Jiao Liu, and Yun Qiu, and Yuan-Ping Tao, and Meng-Chao Wang, and Hui Yao, and Ke-Zhu Hou, and Fang-Ming Gu, and Xuan-Fu Xu
The First Department of General Surgeny, Shidong Hospital, Yangpu District, Shanghai, Anhui Medical University, 999 Shiguang Road, Shanghai, 200438, China.

Recent studies have shown that miR-494-3p is oncogene and has a central role in many solid tumors; however, the role of miR-494-3p in the progression and prognosis of hepatocellular carcinoma (HCC) remains unknown. In this study, it was found that miR-494-3p was up-regulated in HCC tissues. The high level of miR-494-3p in HCC tumors was correlated with aggressive clinicopathological characteristics and predicted poor prognosis in HCC patients. Functional study demonstrated that miR-494-3p significantly promoted HCC cell metastasis in vitro and vivo. Since phosphoinositide 3-kinase/protein kinase-B (PI3K/AKT) signaling is a basic oncogenic driver in HCC, a potential role of miR-494-3p was explored as well as its target genes in PI3K/AKT activation. Of all the predicted target genes of miR-494-3p, the tumor-suppressor phosphatase and tensin homolog (PTEN) were identified. In conclusion, the data we collected could define an original mechanism of PI3K/AKT hyperactivation and sketch the regulatory role of miR-494-3p in suppressing the expression of PTEN. Therefore, targeting miR-494-3p could provide an effective therapeutic method for the treatment of the disease.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Hui Lin, and Zhi-Ping Huang, and Jiao Liu, and Yun Qiu, and Yuan-Ping Tao, and Meng-Chao Wang, and Hui Yao, and Ke-Zhu Hou, and Fang-Ming Gu, and Xuan-Fu Xu
January 2019, Molecular medicine reports,
Hui Lin, and Zhi-Ping Huang, and Jiao Liu, and Yun Qiu, and Yuan-Ping Tao, and Meng-Chao Wang, and Hui Yao, and Ke-Zhu Hou, and Fang-Ming Gu, and Xuan-Fu Xu
June 2018, Oncogene,
Hui Lin, and Zhi-Ping Huang, and Jiao Liu, and Yun Qiu, and Yuan-Ping Tao, and Meng-Chao Wang, and Hui Yao, and Ke-Zhu Hou, and Fang-Ming Gu, and Xuan-Fu Xu
August 2020, Oncology letters,
Hui Lin, and Zhi-Ping Huang, and Jiao Liu, and Yun Qiu, and Yuan-Ping Tao, and Meng-Chao Wang, and Hui Yao, and Ke-Zhu Hou, and Fang-Ming Gu, and Xuan-Fu Xu
January 2015, RNA biology,
Hui Lin, and Zhi-Ping Huang, and Jiao Liu, and Yun Qiu, and Yuan-Ping Tao, and Meng-Chao Wang, and Hui Yao, and Ke-Zhu Hou, and Fang-Ming Gu, and Xuan-Fu Xu
July 2020, Human cell,
Hui Lin, and Zhi-Ping Huang, and Jiao Liu, and Yun Qiu, and Yuan-Ping Tao, and Meng-Chao Wang, and Hui Yao, and Ke-Zhu Hou, and Fang-Ming Gu, and Xuan-Fu Xu
June 2022, World journal of surgical oncology,
Hui Lin, and Zhi-Ping Huang, and Jiao Liu, and Yun Qiu, and Yuan-Ping Tao, and Meng-Chao Wang, and Hui Yao, and Ke-Zhu Hou, and Fang-Ming Gu, and Xuan-Fu Xu
January 2021, Current pharmaceutical design,
Hui Lin, and Zhi-Ping Huang, and Jiao Liu, and Yun Qiu, and Yuan-Ping Tao, and Meng-Chao Wang, and Hui Yao, and Ke-Zhu Hou, and Fang-Ming Gu, and Xuan-Fu Xu
January 2023, Cancer medicine,
Hui Lin, and Zhi-Ping Huang, and Jiao Liu, and Yun Qiu, and Yuan-Ping Tao, and Meng-Chao Wang, and Hui Yao, and Ke-Zhu Hou, and Fang-Ming Gu, and Xuan-Fu Xu
January 2018, OncoTargets and therapy,
Hui Lin, and Zhi-Ping Huang, and Jiao Liu, and Yun Qiu, and Yuan-Ping Tao, and Meng-Chao Wang, and Hui Yao, and Ke-Zhu Hou, and Fang-Ming Gu, and Xuan-Fu Xu
April 2017, Cancer science,
Copied contents to your clipboard!